If you snore, wake up gasping, or feel exhausted no matter how long you sleep, you might have sleep apnea.
And GLP-1 medications may help — not just because of weight loss, but possibly in ways we're just beginning to understand.
What Is Sleep Apnea?
Sleep apnea happens when your airway closes partially or completely during sleep. You stop breathing — sometimes hundreds of times per night. Your brain wakes you up just enough to restart breathing. You don't remember it happening, but your body does.
Common symptoms:
- Loud snoring
- Waking up gasping or choking
- Daytime exhaustion
- Morning headaches
- Trouble concentrating
- Irritability
Obesity is the biggest risk factor for sleep apnea. Extra weight around the neck puts pressure on the airway, making it more likely to collapse during sleep.
What the Research Shows
SURMOUNT-OSA Trial Results (2024-2026)
The SURMOUNT-OSA trials established tirzepatide as the first FDA-approved medication for obstructive sleep apnea.
Zepbound FDA Approval for Sleep Apnea (2024)
On December 20, 2024, the FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This was a landmark — the first medication ever approved for this condition. The FDA granted it Fast Track, Priority Review, and Breakthrough Therapy designations.
The approval was based on two Phase 3 trials called SURMOUNT-OSA:
SURMOUNT-OSA 1 (no CPAP at baseline):
- 234 adults with moderate-to-severe OSA and obesity who weren't using CPAP
- 52 weeks of tirzepatide (max tolerated dose 10 mg or 15 mg)
- AHI reduced by 25.3 events/hour with tirzepatide vs 5.3 with placebo
- Average weight loss consistent with tirzepatide's profile
- Many key health markers improved: hypoxic burden, inflammation (CRP), and blood pressure
SURMOUNT-OSA 2 (on CPAP at baseline):
- 235 adults with moderate-to-severe OSA using CPAP therapy
- 52 weeks of tirzepatide
- AHI reduced by 29.3 events/hour with tirzepatide vs 5.5 with placebo
- Participants on tirzepatide reduced their CPAP usage over time
- Similar improvements in weight, inflammation, and cardiovascular markers
The SELECT Trial Substudy (2024)
A substudy of the large SELECT trial looked at semaglutide (Wegovy) in people with obesity and moderate-to-severe obstructive sleep apnea.
Results:
- People on semaglutide had a significant reduction in sleep apnea severity
- The improvement was directly related to the amount of weight lost
- More weight loss = greater improvement in sleep apnea
- About 33% of people on semaglutide achieved complete resolution of their sleep apnea (AHI below 5)
Other Studies
Multiple studies have found:
- Weight loss from GLP-1s reduces sleep apnea severity
- Some people are able to reduce or stop using their CPAP machine after significant weight loss
- GLP-1s may improve sleep quality independently of sleep apnea improvement
New at ADA 2026: Wegovy Cuts New Sleep Apnea Cases by 52%
At the American Diabetes Association's 2026 Scientific Sessions (June 7, New Orleans), Novo Nordisk presented a post hoc analysis from the SELECT trial looking at semaglutide 2.4 mg (Wegovy) and sleep apnea.
Key findings:
- Semaglutide 2.4 mg was linked to a 52% lower incidence of new OSA (HR 0.48, p<0.001) compared to placebo
- Among people without OSA at the start: 30 new cases with semaglutide vs 65 with placebo
- Semaglutide also reduced major cardiovascular events (MACE) regardless of whether someone had OSA
- The analysis included 2,550 participants (14.5% of the trial) who reported having OSA at baseline
This is important because it suggests Wegovy may not just treat existing sleep apnea — it may help prevent it from developing in the first place.
Important note: Semaglutide is not FDA-approved for sleep apnea. These are exploratory findings that need more research. Zepbound remains the only medication with FDA approval for OSA.
Zepbound Dosing for Sleep Apnea
If you're prescribed Zepbound for OSA, here's the dosing:
- Start: 2.5 mg once weekly for 4 weeks (same as the weight loss start dose)
- Titrate up: Increase by 2.5 mg every 4 weeks (5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg)
- Maintenance for OSA: 10 mg or 15 mg once weekly
- Weight loss only maintenance: 5 mg, 10 mg, or 15 mg
The key difference: for sleep apnea, the maintenance dose needs to be at least 10 mg. The 5 mg dose — which works for weight maintenance — was not studied for OSA. The SURMOUNT-OSA trials used the maximum tolerated dose (10 mg or 15 mg) and found these higher doses were needed for meaningful AHI reduction.
2026 Meta-Analysis Confirms the Pattern
A systematic review published in Sleep and Breathing (April 2026) analyzed multiple GLP-1 RA studies for OSA:
- GLP-1 RAs consistently reduce AHI, with tirzepatide showing reductions up to 29.3 events/hour
- Average weight loss of 19.6% over 52 weeks with tirzepatide
- Improvements in hypoxic burden, CRP (inflammation), and systolic blood pressure
- The review concluded that incretin-based therapies are effective for treating OSA by targeting its metabolic drivers
How GLP-1s Help Sleep Apnea
1. Weight Loss
This is the biggest factor. Losing weight reduces fat around the neck and throat, which opens the airway.
- Even a 10% reduction in body weight can significantly improve sleep apnea
- Greater weight loss leads to greater improvement
2. Reduced Inflammation
Sleep apnea is linked to inflammation in the upper airway. GLP-1s reduce inflammation throughout the body, which may help reduce airway swelling.
3. Better Sleep Quality
GLP-1s may improve sleep quality directly, beyond their effect on sleep apnea. Better sleep means better energy, mood, and metabolic health.
What This Means for You
If You Have Sleep Apnea
GLP-1s may be a helpful addition to your treatment plan — especially if you also have obesity or type 2 diabetes.
Zepbound (tirzepatide) is now FDA-approved for OSA. If you have moderate-to-severe obstructive sleep apnea with obesity, ask your doctor about it. It may be covered by insurance for this indication even if you don't have diabetes.
Wegovy (semaglutide) is not FDA-approved for OSA but has strong trial data showing benefit. Your doctor may prescribe it off-label for sleep apnea.
Important: Don't stop using your CPAP machine without talking to your sleep doctor. Weight loss takes time, and your airway needs support in the meantime.
If You Think You Might Have Sleep Apnea
Talk to your doctor about getting a sleep study. Sleep apnea is serious — it increases the risk of high blood pressure, heart disease, stroke, and diabetes.
If You're on GLP-1s and Notice Better Sleep
You're not imagining it. Weight loss from GLP-1s genuinely improves sleep apnea for many people. For a broader look at how GLP-1s affect your rest — including insomnia, vivid dreams, and circadian rhythm — read our GLP-1 and sleep guide.
Don't Stop Your CPAP Too Soon
Sleep apnea products:
- Wedge pillow - elevates head to reduce snoring
- White noise machine - helps with sleep quality
Some people lose weight on GLP-1s and assume their sleep apnea is gone. They stop using their CPAP. Big mistake.
What to do instead:
- Keep using your CPAP
- After significant weight loss (10%+ of body weight), ask your sleep doctor for a follow-up sleep study
- If the study shows your sleep apnea has resolved, your doctor may clear you to stop CPAP
- Don't make this decision on your own
When to See Your Doctor
- You snore loudly and wake up gasping
- You're exhausted during the day despite sleeping enough hours
- Your partner notices you stop breathing during sleep
- You want to discuss whether GLP-1s might help your sleep apnea
- You've lost significant weight and want to re-evaluate your CPAP needs
The Bottom Line
GLP-1 medications can improve sleep apnea through weight loss and possibly other mechanisms. But they're not a replacement for CPAP therapy — at least not right away.
Your action items:
- If you suspect sleep apnea, get a sleep study
- If you have sleep apnea, keep using your CPAP even if you start losing weight
- After significant weight loss, ask for a follow-up sleep study
- Talk to your doctor about whether GLP-1s might help your sleep apnea
- Don't stop CPAP without medical clearance
Better sleep is one of the most underrated benefits of GLP-1 treatment. If you've been struggling with sleep apnea, weight loss may be the most effective thing you can do.
This article is for informational purposes only and does not replace medical advice. Always talk to your healthcare provider about sleep apnea and CPAP use. Do not stop using your CPAP machine without medical guidance.
Found this helpful? Share it with someone who snores — they might need to hear this.
